Author: OurCrowd

[CorrActions in TechCrunch] CorrActions raises $2.7M to help avoid errors in human-machine interactions

May 27, 2021 |

CorrActions, a noninvasive neuroscience startup that uses sensor data to evaluate a user’s cognitive state due to drowsiness, alcohol, fatigue and other issues, today announced that it has raised a $2.7 million seed round. Early-stage fund VentureIsrael, seed fund Operator Partners and the Israeli Innovation Authority are backing the company, which is based out of OurCrowd’s Labs/02 incubator. Read...

Read More

[BrainQ in PR Newswire] BrainQ gets FDA Breakthrough status for its device for reducing disability following stroke

Feb 11, 2021 |

JERUSALEM, Feb. 11, 2021 /PRNewswire/ — BrainQ, the Israeli start-up with a therapeutic solution to reduce disability following stroke, announced today that the United States Food and Drug Administration (FDA) has designated its AI-powered technology as a Breakthrough Device. The designation, which was based on BrainQ’s latest randomized controlled clinical trial results for ischemic stroke patients, provides BrainQ with the opportunity to work closely with the FDA to expedite development plans and premarket clearance. Breakthrough status also gives BrainQ access to the new Medicare Coverage of Innovative Technology (MCIT) pathway, allowing for Medicare coverage to be provided concurrently with FDA market authorization. Read more...

Read More